Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Doke 2023 Nat Metab

From Bioblast
Publications in the MiPMap
Doke T, Mukherjee S, Mukhi D, Dhillon P, Abedini A, Davis JG, Chellappa K, Chen B, Baur JA, Susztak K (2023) NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury.

Β» Nat Metab 5:414-30. PMID: 36914909 Open Access

Doke Tomohito, Mukherjee Sarmistha, Mukhi Dhanunjay, Dhillon Poonam, Abedini Amin, Davis James G, Chellappa Karthikeyani, Chen Beishan, Baur Joseph A, Susztak Katalin (2023) Nat Metab

Abstract: Our understanding of how global changes in cellular metabolism contribute to human kidney disease remains incompletely understood. Here we show that nicotinamide adenine dinucleotide (NAD+) deficiency drives mitochondrial dysfunction causing inflammation and kidney disease development. Using unbiased global metabolomics in healthy and diseased human kidneys, we identify NAD+ deficiency as a disease signature. Furthermore using models of cisplatin- or ischaemia-reperfusion induced kidney injury in male mice we observed NAD+ depletion Supplemental nicotinamide riboside or nicotinamide mononucleotide restores NAD+ levels and improved kidney function. We find that cisplatin exposure causes cytosolic leakage of mitochondrial RNA (mtRNA) and activation of the cytosolic pattern recognition receptor retinoic acid-inducible gene I (RIG-I), both of which can be ameliorated by restoring NAD+. Male mice with RIG-I knock-out (KO) are protected from cisplatin-induced kidney disease. In summary, we demonstrate that the cytosolic release of mtRNA and RIG-I activation is an NAD+-sensitive mechanism contributing to kidney disease.

β€’ Bioblast editor: Plangger M β€’ O2k-Network Lab: US PA Philadelphia Baur JA

Labels: MiParea: Respiration, Genetic knockout;overexpression, mt-Medicine  Pathology: Other 

Organism: Human  Tissue;cell: Kidney  Preparation: Isolated mitochondria 

Regulation: Redox state  Coupling state: OXPHOS  Pathway: N, CIV  HRR: Oxygraph-2k